SOFIVA GENOMICS Co (ROCO:6615) LT-Debt-to-Total-Asset : 0.05 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is SOFIVA GENOMICS Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. SOFIVA GENOMICS Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.05.

SOFIVA GENOMICS Co's long-term debt to total assets ratio declined from Sep. 2023 (0.07) to Sep. 2024 (0.05). It may suggest that SOFIVA GENOMICS Co is progressively becoming less dependent on debt to grow their business.

SOFIVA GENOMICS Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for SOFIVA GENOMICS Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SOFIVA GENOMICS Co LT-Debt-to-Total-Asset Chart

SOFIVA GENOMICS Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.11

0.09

0.08

0.06

SOFIVA GENOMICS Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.06	0.06	0.06	0.05

SOFIVA GENOMICS Co LT-Debt-to-Total-Asset Calculation

SOFIVA GENOMICS Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	49.152	/	767.138
	=	0.06

SOFIVA GENOMICS Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	41.095	/	776.491
	=	0.05

SOFIVA GENOMICS Co (ROCO:6615) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

SOFIVA GENOMICS Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of SOFIVA GENOMICS Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SOFIVA GENOMICS Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SOFIVA GENOMICS Co Ltd (ROCO:6615) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66-1, Sec. 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043

Website

https://www.sofivagenomics.com.tw

SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, pre-natal and neonatal genetic testing and medical testing and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.

SOFIVA GENOMICS Co Headlines

No Headlines